Ginkgo Bioworks announced on January 13, 2025, a research collaboration with Universal Cells, an Astellas company, to optimize next-generation induced pluripotent stem cell (iPSC)-derived cancer cell therapies. This partnership focuses on tackling the complex challenges associated with developing therapies for solid tumors.
The collaboration will combine Universal Cells' proprietary iPSC-derived cell technologies with Ginkgo's expertise in designing and screening large CAR libraries and its high-throughput immune cell engineering platform. The goal is to accelerate the development of more potent and durable cell therapies while maintaining manufacturability at scale.
Ginkgo's platform leverages computational tools, deep expertise in library assembly and screening, and rigorous statistical analysis to discover and engineer optimal therapeutic designs with greater speed and precision. This expansion into the cell therapy portfolio represents a significant milestone for Ginkgo.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.